Atlas of Genetics and Cytogenetics in Oncology and Haema tology

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Portal   Teaching

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA


A. Majid Khatib
INSERM U1029, University Bordeaux , Bat. B2 Ouest
Allée Geoffroy St Hilaire CS50023
3, 3615 PESSAC CEDEX, France
tel : 33-(0)540003857 33-(0)675243164

Fields of competence: Protein maturation, Tumour microenvironment, Metastasis, Angiogenesis

University education:

  • 1992: Master: D. E. A. de Physiologie et Physiopathologie, University of Paris 7
  • 1997: PhD: Thèse d'Université en Science de la Vie et de la Santé, University of Paris
  • 2008: Habilitation à Diriger les Recherches (HDR). University of Paris 7

    Professional cursus:

  • Since 2011: Associate director INSERM, U1029 Bordeaux
  • Since 2011: Research Director INSERM, U1029 Bordeaux
  • 2008-2011: Research Director INSERM, U940 Paris
  • 2004-2008: Tenure Full position, CR1. INSERM, Paris
  • 2004-2011: Head of the oncogenesis and metastasis group at INSERM UMR940, Paris
  • 2003-2006: Co-Director of proteomic facilities at Hyam Institute, Paris
  • 2003: Avenir Laureate, INSERM, U716, Paris
  • 2002: Scientist, OHRI, Ottawa, Canada
  • 2002: Assistant Professor, University of Ottawa, Canada
  • 1996-2000: Postdoctoral fellow. Laboratory of metastasis. University of McGill, Montreal,

    Prizes and honours:

  • 2012-2015: 'Chair d'Excellence University' of Bordeaux
  • 2010-2012: Cooperation FRSQ-INSERM, France-Canada
  • 2009-2011 : Holder of Programme Samuel-De Champlain, France-Quebec.
  • 2009: Designated to participate in Japanese-French Frontiers of Science, Kanagawa, Japan
  • 2007-2009: Cooperation FRSQ-INSERM, France-Canada
  • 2006: Gordon Conference prize, New London, USA
  • 2006-2009: Interface contract between the INSERM and St Louis Hospital, Paris
  • 2006-2009: Equipe Labellisée La LIGUE 2006, La Ligue Contre Le Cancer (LLCC), Paris,
  • 2003-2006: Avenir Award, INSERM 2003 :
  • 2003: Canadian foundation for innovation (
  • 2000: Royal Victoria Hospital Institute Award (RVH), Montreal, Canada
  • 1997: Brigadier-General Hebert Stanley Birkett Memorial Award, McGill University, Canada
  • 1995: Laboratories Biostabilex-URAP prize, Paris
  • 1994: Pierre Fabre Médicament Award, Paris

    Industrial exploitation of results: 10 patents
    1 License
    Participation to national and international scientific networks: (Major)
    Canceropole GSO Axe3 coordinator, Cancer Regional network, University Bordeaux, Gordon conference (NH, USA), Ethic comity 73, AACR, International Cytokine Society, American Society for Investigative Pathology, French Angiogenesis Society, Herpes-Cancer Network, Recherche Dermatologique (card).

    Scientific expertise:
    Research Council of Canada, Canadian Breast Cancer Foundation, South Plains Foundation (Texas), Research Foundation Flanders (FWO, Belgium), Wellcome trust (UK), Swiss National Science Foundation (Switzerland), La Ligue Contre Le Cancer (LLCC), INCA, ANR, GSO, Chercheuses/eurs D'avenir : La Région Languedoc Roussillon, Tenon Hospital-INSERM Center commission for Scientists recruitment.

    Journals reviewer:
    Journal of clinical investigation, Cancer Research, The American Journal of Pathology, Journal of Molecular Medicine, Cytokine, International Journal of cancer, Cellular Oncology, Blood, BMC Cancer, BMC Biochemistry, Molecular Cancer, Journal of Gastroenterology; FASEB Journal, The International Journal of Biochemistry, Journal Drugs News and perspectives, Neoplasia, Clinical Cancer Research, Neurosciences letters, Arthritis and Rheumatism, The International Journal of Biochemistry, Journal Drugs News and perspectives, Clinical Cancer Research, Tumor Biology.

    Selected publications

    1. Tomé M, Pappalardo A, Soulet F, López JJ, Olaizola J, Leger Y, Dubreuil M, Mouchard A, Fessart D, Delom F, Pitard V, Bechade D, Fonck M, Rosado JA, Ghiringhelli F, Déchanet-Merville J, Soubeyran I, Siegfried G, Evrard S, Khatib AM. Inactivation of proprotein convertases in T cells inhibits PD-1 expression and creates a favorable immune microenvironment in colorectal cancer.Cancer Res. 2019 Jul 29. pii: canres.0086.2019.
    2. Adam F,* Khatib AM,* Lopez JJ, Vatier C, Turpin S, Muscat A, Soulet F, Aries A, Jardin I, Bobe R, Stepanian A, de Prost D, Dray C, Rosado JA, Valet P, Feve B, Siegfried G. Apelin: an antithrombotic factor that inhibits platelet function. Blood. 2016 Feb 18;127(7):908-20.. * equal contribution
    3. Sfaxi F, Scamuffa N, Lalou C, Ma J, Metrakos P, Siegfried G, Ragg H, Bikfalvi A, Calvo F, Khatib AM. Repression of liver colorectal metastasis by the serpin Spn4A a naturally occurring inhibitor of the constitutive secretory proprotein convertases. Oncotarget. 2014 Jun 30;5(12):4195-210.
    4. Scamuffa N, Siegfried G, Bontemps Y, Ma L, Basak A, Cherel G, Calvo F, Seidah NG, Khatib AM. Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. J Clin Invest. 2008 Jan;118(1):352-63.
    5. Scamuffa N, Basak A, Lalou C, Wargnier A, Marcinkiewicz J, Siegfried G, Chrétien M, Calvo F, Seidah NG, Khatib AM.Regulation of prohepcidin processing and activity by the subtilisin-like proprotein convertases Furin, PC5, PACE4 and PC7. Gut. 2008 Nov;57(11):1573-82.
    6. Lapierre M, Siegfried G, Scamuffa N, Bontemps Y, Calvo F, Seidah NG, Khatib AM. Opposing function of the proprotein convertases furin and PACE4 on breast cancer cells' malignant phenotypes: role of tissue inhibitors of metalloproteinase-1. Cancer Res. 2007 Oct 1;67(19):9030-4.


      Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case reports   Journals   Portal   Teaching   

      X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA